Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin hormone primarily produced by L-cells in the small intestine, playing a major role in regulating blood sugar levels, appetite, and overall metabolic health
If GLP-1 agonists pose a similar risk, thats important to knowand if they dont, it could further accelerate the sea change occurring in our approach to treating obesity. The studys results, published in JAMA Psychiatry , suggest that the similarities in outcome between the two approaches do not include that potential downside
While these numbers show effectiveness, they also suggest that expectations should be managed, especially given the significant financial investment
This can be really hard to deal with, especially in the stomach and the arms
Is Retatrutide Relevant for Type 2 Diabetes Research Models In clinical studies, retatrutide demonstrated significant reductions in HbA1c and fasting plasma glucose in participants with type 2 diabetes, alongside the body weight effects observed in the broader obesity cohort [7]
For diabetic patients considering Retatrutide, the cardiovascular benefits may actually be more important than the blood sugar effects
